SUN 131

Drug Profile

SUN 131

Alternative Names: SUN131

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Senju Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ocular inflammation

Most Recent Events

  • 01 Oct 2014 Phase-II clinical trials in Ocular inflammation in USA (Transdermal) (NCT02338648)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top